Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS' skin cancer drug

The US Food and Drug Administration has approved Bristol-Myers Squibb's Yervoy for the treatment of unresectable or metastatic melanoma

The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's (BMS) Yervoy (ipilimumab) for the treatment of unresectable or metastatic melanoma.

The drug is the first approved therapy in the US that demonstrates a 'significant improvement' in overall survival for patients whose skin cancer cannot be treated with surgery or has spread to other organs.

The decision date for approval had been moved back from December 25, 2010, with the FDA determining that additional time was required to complete the review of the biologics licence application.

Yervoy recently showed positive results from a phase III study that compared the drug in combination with dacarbazine chemotherapy to the chemotherapy regimen alone.

Lamberto Andreotti, CEO, BMS said: "Today's approval of Yervoy is an example of Bristol-Myers Squibb living its mission of developing and delivering innovative medicines that address the unmet needs of patients with serious diseases."

BMS has said it expects to begin shipment of Yervoy within weeks.

A post-marketing study will also be carried out comparing the safety and efficacy of the 3mg/kg dose of the drug against an investigational 10mg/kg dose.

28th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics